Assessing Optimal XR-Buprenorphine Initiation Points in Jail
Status:
Not yet recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
The goal of this study is to compare two approaches for commencing pharmacotherapy with
injectable buprenorphine for opioid use disorder (OUD) among jail inmates: (1) at the time of
admission or (2) shortly before release. A sample of eligible inmates with sentences of less
than 180 days will be randomly assigned to (1) initiating extended-release buprenorphine
(XR-B) treatment at the time of admission (n=80), or (2) initiating XR-B treatment within 30
prior to their scheduled release date (n=80). The groups will be compared with regard to (1)
how likely they were to participate in treatment, (2) levels of in-jail opioid use (via
post-release interviews), (3) continuation of pharmacotherapy and other OUD treatment in the
community, and (4) levels of opioid use 4 and 12 weeks following discharge (self-report and
incentivized voluntary urine tests).